Literature DB >> 4920933

Aminoglutethimide: a "side-effect" turned to therapeutic advantage.

S W Hughss, D M Burley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4920933      PMCID： PMC2467063          DOI： 10.1136/pgmj.46.537.409

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  35 in total

1.  EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN.

Authors:  E E WERK; J MACGEE; L J SHOLITON
Journal:  J Clin Invest       Date:  1964-09       Impact factor: 14.808

2.  Elipten in the treatment of organic epilepsy.

Authors:  G D LAVECK
Journal:  Dis Nerv Syst       Date:  1960-04

3.  One thousand cases of late onset epilepsy.

Authors:  S SHEEHAN
Journal:  Ir J Med Sci       Date:  1958-06       Impact factor: 1.568

4.  [Clinical experiences with aminoglutethimide (Elipten), a new inhibitor of steroid biosynthesis in the adrenal gland].

Authors:  K Horký; O Küchel; I Gregorová; J Jiránková; Z Matys
Journal:  Schweiz Med Wochenschr       Date:  1968-11-23

5.  Antithyroid and antiadrenocortical activity of aminoglutethimide.

Authors:  J A Pittman; R W Brown
Journal:  J Clin Endocrinol Metab       Date:  1966-09       Impact factor: 5.958

Review 6.  Inhibitors of adrenal cortical function.

Authors:  R Gaunt; J J Chart; A A Renzi
Journal:  Ergeb Physiol       Date:  1965

7.  [Clinical and biological study of an inhibitor of adrenocortical hormone synthesis: aminoglutethinide].

Authors:  M Philbert; M H Laudat; P Laudat; H Bricaire
Journal:  Ann Endocrinol (Paris)       Date:  1968 Mar-Apr       Impact factor: 2.478

8.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

9.  Aminoglutethimide (Elipten CIBA)--a new inhibitor of steroid biosynthesis.

Authors:  K Horký; O Küchel
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

10.  Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome.

Authors:  D E Schteingart; R Cash; J W Conn
Journal:  JAMA       Date:  1966-11-28       Impact factor: 56.272
View more
  9 in total

1.  Proceedings: Preliminary pharmacological study of N,2-dimethyl,2-(p-aminophenyl) succinimide.

Authors:  P J Nicholls; I T Scoular
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

Review 2.  Drug-induced endocrine disorders.

Authors:  D Evered; P P Yeo
Journal:  Drugs       Date:  1977-05       Impact factor: 9.546

3.  Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary.

Authors:  P R Hunter; W Ross; R Hall; D B Cook
Journal:  Proc R Soc Med       Date:  1974-12

4.  Effects of aminoglutethimide (Elipten Ciba), a steroid biosynthesis blocking agent, on adrenal glands in Cushing's syndrome.

Authors:  K Motlík; P Pinsker; L Stárka; E Hradec
Journal:  Virchows Arch A Pathol Pathol Anat       Date:  1973

Review 5.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 6.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 7.  Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.

Authors:  R J Santen
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.

Authors:  M R Robinson; B S Thomas
Journal:  Br Med J       Date:  1971-11-13

Review 9.  Towards understanding aromatase inhibitory activity via QSAR modeling.

Authors:  Watshara Shoombuatong; Nalini Schaduangrat; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2018-07-20       Impact factor: 4.068
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.